Monographie - Diltiazem hydrochloride

Pēdējā atjaunošana :
08/05/2024

Diltiazem hydrochloride

Ķīmiskā uzbūve

Oriģinālais nosaukums

Tirdzniecības nosaukumi ir apzīmējoši un palīgvielas var atšķirties dažādām valstīm un laboratorijām

Alcalix	Argentīna
Altiazem	Itālija
Angizem	Itālija
Balcor	Brazīlija
Cardizem	Amerikas Savienotās Valstis
Cirilen	Ekvadora
Diltiazem	Amerikas Savienotās Valstis, Ekvadora, Kanāda
Diltizem	Turcija
Dilzem	Austrija, Indija, Polija, Šveice, Ungārija, Vācija
Dilzene	Itālija
Herbesser	Japāna, Malaizija
Masdil	Spānija
Tildiem	Francija, Grieķija, Holande, Itālija, Luksemburga

Literatūras saraksts : Diltiazem hydrochloride

	Tips	Publicēšana
198	Žurnāls	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
314	Žurnāls	Chiu MF, Schwartz ML. Visual compatibility of injectable drugs used in the intensive care unit. Am J Health-Syst Pharm 1997 ; 54: 64-65.
524	Žurnāls	Farquhar Zanetti LA. Visual compatibility of diltiazem with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1992 ; 49: 1911.
813	Žurnāls	Akkermann SR, Zhang H, Mullins RE, Yaughn K. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions. Am J Health-Syst Pharm 1999 ; 56: 63-68.
1067	Žurnāls	Zeidler C, Dettmering D, Schrammel W, Spieteller M. Compatibility of various drugs used in intensive care medicine in polyethylene, PVC and glass infusion containers. EJHP 1999 ; 5: 106-110.
1462	Žurnāls	De Vroe C, de Muynck C, Remon JP, Scheldewaert R, Colardyn F. The availability of diltiazem: a study on the sorption by intravenous delivery systems and on the stability of the drug. J Pharm Pharmacol 1989 ; 41: 273-275.
1508	Žurnāls	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1625	Žurnāls	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1712	Žurnāls	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Žurnāls	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Žurnāls	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1801	Žurnāls	Feddema S, Rusho WJ, Tyler LS, Barker B. Physical compatibility of vasopressin with medications commonly used in cardiac arrest. Am J Health-Syst Pharm 2003 ; 60: 1271-1272.
1803	Žurnāls	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1851	Žurnāls	Andrisano V, Hrelia P, Gotti R, Leoni A, Cavrini V. Photostability and phototoxicity studies on diltiazem. J Pharm Biomed Anal 2001 ; 25, 3-4: 589-597.
1944	Žurnāls	Hartman CA, Faria CE, Mago K. Visual compatibility of bivalirudin with selected drugs. Am J Health-Syst Pharm 2004 ; 61: 1774.
1964	Žurnāls	Hartman CA, Baroletti SA, Churchill WW et al. Visual compatibility of argatroban with selected drugs. Am J Health-Syst Pharm 2002 ; 59: 1784-1785.
2108	Žurnāls	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2247	Žurnāls	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Žurnāls	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Žurnāls	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2346	Žurnāls	Newland A.M, Mauro V.F, Alexander K.S. Physical compatibility of metoprolol tartrate injection with selected cardiovascular agents Am J Health-Syst Pharm 2009 ; 66: 986-987.
3210	Žurnāls	Jasti Bhaskara R, Saraf Poonam. Compatibility of Parenteral Furosemide with Seventeen Secondary Drugs Used in Standard Concentrations. Int J Pharm Compound 2011 ; 15, 3: 259-261.
3249	Žurnāls	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	Žurnāls	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3409	Žurnāls	Kaushal G, Sayre B.E, Prettyman T. Stability of extemporaneously compounded diltiazem hydrochloride infusions stored in polyolefin bags Am J Health-Syst Pharm 2013 ; 70:894-899.
3429	Žurnāls	Foushee J.A, Fox L.M, Gormley L.R, Lineberger M.S. Physical compatibility of cisatracurium with selected drugs during simulated Y-site administration Am J Health-Syst Pharm 2015 ; 72:483-486
3595	Laboratorija	Aciclovir - Summary of Product Characteristics Hospira 2009
3764	Žurnāls	Jakimczuk P.J, Churchwell M.D, Howard M.S, Mauro V.F, Alexander K.S, Boddu S.H.S. Compatibility of argatroban injection with select antiarrhythmic drugs Am J Health-Syst Pharm 2014 2014; 71: 1831-1832.
3827	Plakāts	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Plakāts	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Plakāts	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
4055	Žurnāls	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Žurnāls	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4433	Žurnāls	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4434	Žurnāls	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4528	Žurnāls	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4556	Žurnāls	Dobson, S.R, Mauro, V.F, Boddu, S.H.S, Churchwell, M.D. The Physical Compatibility of Clinically Used Concentrations of Diltiazem Hydrochloride With Heparin Sodium. J Pharm Technol 2020 ; 36, 4: 126-129.
4650	Laboratorija	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4801	Žurnāls	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Mentions Légales